Drug Trial Radar · NCT06677710
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
34
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Indapta Therapeutics, INC.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Conditions
- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Non-Active Secondary Progressive Multiple Sclerosis
- Non-Active SPMS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Autoimmune Diseases
- Demyelinating Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions
IDP-023Drug
NK cell therapy
OcrelizumabDrug
Anti-CD20 antibody therapy
Interleukin-2Drug
Immune cytokine
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
MesnaDrug
Chemoprotectant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEs and SAEs - (Part 1)Time frame: 1 year
- Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with IL-2 and Ocrelizumab (Part 1)Time frame: up to 21 days
- Change in cellular response of autoreactive immune cells to antigen (Part 2)Time frame: 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
University of Colorado Hospital
Aurora, Colorado
AdventHealth Orlando - Adventist Health System/Sunbelt, Inc.
Orlando, Florida
Kansas University Medical Center
Kansas City, Kansas
Washington University in St. Louis
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.